[G17-10] Nivolumab Squamous cell carcinoma of the head and neck - Addendum to A17-24
Last updated 17.11.2017
Project no.:
G17-10
Commission:
Commission awarded on 09.10.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A18-40 | Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A17-24 | Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-11-17 A G-BA decision was published.